Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Cardiovasc Ther. 2021 Jan 23;2021:2680107. doi: 10.1155/2021/2680107. eCollection 2021.
The probable impact of growth hormone (GH) as a heart failure (HF) treatment strategy is still less investigated. Therefore, we aimed to evaluate the relation of 3-month GH prescription on left ventricular ejection fraction (LVEF), interventricular septum (IVS), posterior left ventricle (LV) thickness, end systolic and end diastolic diameters (ESD and EDD), and pulmonary arterial pressure (PAP) among Iranian individuals suffering from HF due to MI attack.
A total of 16 clinically stable participants with HF diagnosis and LVEF < 40% were selected for enrollment in this pilot randomized double-blinded study. They were randomly assigned equally to groups received 5 IU subcutaneous GH or placebo. Injections were done every other day for a total of 3-month duration. After termination of intervention and nine months afterwards, cardiac outcomes were assessed.
Baseline and 12-month posttrial participants' characteristics were similar. LVEF was increased significantly by three months started from baseline in individuals receiving GH (32 ± 3.80% to 43.80 ± 4.60%, = 0.002). During the next 9 months of follow-up concurrent with cessation of injections, LVEF was declined (43.80 ± 4.60% to 32.20 ± 6.97%, = 0.008). LVEF and ESD were remarkably higher and lower in GH group compared with controls by the end date of injections (43.80 ± 4.60% vs. 33.14 ± 4.84%, = 0.02 and 39.43 ± 3.45 mm vs. 33 ± 3.16 mm, = 0.03, respectively). No other considerable association was found in terms of other predefined variables in neither GH nor placebo groups.
GH administration in HF patients was associated with increased LVEF function. Several randomized clinical trials are necessary proving this relation. This trial is registered with IRCT201704083035N1.
生长激素（GH）作为心力衰竭（HF）治疗策略的可能影响仍研究较少。因此，我们旨在评估 3 个月 GH 处方对伊朗因心肌梗死导致 HF 个体的左心室射血分数（LVEF）、室间隔（IVS）、左心室后壁（LV）厚度、收缩末期和舒张末期直径（ESD 和 EDD）和肺动脉压（PAP）的关系。
共选择了 16 名临床稳定的 HF 诊断和 LVEF<40%的患者参与这项初步随机双盲研究。他们被随机分为两组，分别接受 5IU 皮下 GH 或安慰剂。注射每两天一次，共 3 个月。干预结束后 9 个月评估心脏结局。
基线和 12 个月后试验参与者的特征相似。接受 GH 的个体的 LVEF 在 3 个月时从基线开始显著增加（32±3.80%至 43.80±4.60%， =0.002）。在接下来的 9 个月的随访中，随着注射的停止，LVEF 下降（43.80±4.60%至 32.20±6.97%， =0.008）。在注射结束时，GH 组的 LVEF 和 ESD 显著高于对照组（43.80±4.60%比 33.14±4.84%， =0.02 和 39.43±3.45mm 比 33±3.16mm， =0.03）。GH 组和安慰剂组在其他预设变量方面均未发现其他显著相关性。
GH 给药可改善 HF 患者的 LVEF 功能。有必要进行更多的随机临床试验来证明这一关系。本试验已在 IRCT201704083035N1 注册。
